share_log

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

花旗集團維持對Apellis Pharmicals的買入,將目標股價下調至60美元
Benzinga ·  05/08 15:34

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $67 to $60.

花旗集團分析師伊加爾·諾霍莫維茨維持Apellis Pharmicals(納斯達克股票代碼:APLS)的買入並將目標股價從67美元下調至60美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論